LSL Pharma Group Inc
- LAST PRICE0.4500
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots0.4550/ 2
- Ask / Lots0.4600/ 38
- Open / Previous Close0.4500 / 0.4500
- Day Range
- 52 Week Range
- Volume6,500
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | LSL |
|---|---|---|
| 09:44 ET | 1000 | 0.45 |
| 11:20 ET | 5500 | 0.45 |
Nov 6, 2024
Oct 24, 2024
LSL PHARMA GROUP ANNOUNCES THE FIRST INTEREST PAYMENT ON THE CONVERTIBLE DEBENTURES LISTED AS LSL.DB, from 7:00AM ET on Thursday Oct 24, 2024 by Dow Jones
7:00AM ET on Thursday Oct 24, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
LSL Pharma Group Inc | 52.0M | -19.4x | --- |
Medicus Pharma Ltd | 31.5M | -0.8x | --- |
BioNxt Solutions Inc | 26.6M | -3.9x | --- |
Devonian Health Group Inc | 19.3M | -6.0x | --- |
Pharmather Holdings Ltd | 19.0M | -9.0x | --- |
1CM Inc | 29.4M | -53.0x | --- |
Company Information
LSL Pharma Group Inc. is a Canadian integrated pharmaceutical company. The Company is specialized in the development, manufacturing and commercialization of sterile ophthalmic pharmaceuticals, as well as natural health products in solid dosage forms. It specializes in the manufacturing and marketing of natural health products (NHPs). The Company manufactures a range of NHPs in liquid, powder and capsule form, sold under its own brand or under private labels. Its manufacturing activities include blistering, encapsulation, sachet and jar filling. The Company's subsidiaries include Steri-Med Pharma Inc., LSL Laboratory Inc. and Groupe Immobilier LSL inc.
Contact Information
- Headquarters
- 540, rue d'Avaugour, Office 1800BOUCHERVILLE, QC, Canada J4B 0G6
- Phone
- 450-681-7744
- Fax
- 450-681-8400
Executives
- Chairman of the Board, President, Chief Executive Officer
- Francois Roberge
- Chief Financial Officer, Executive Vice President
- Luc Mainville
- Vice President - Communications
- Marc Boudreault
- Director
- Stuart Fowler
- Director
- Giuseppe Soccodato
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $52.0M |
|---|---|
Revenue (TTM) | $14.3M |
Shares Outstanding | 115.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-0.02 |
Book Value | $0.10 |
P/E Ratio | -19.4x |
Price/Sales (TTM) | 3.6 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -4.54% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
